Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABO2109 in Adjuvant Therapy of Solid Tumors
NCT07583953Phase 1Not yet recruiting
- Sponsor
- Abogen Bioscience
- Start
- Apr 2026
- Primary completion
- Jan 2029
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
01
Overview
Phase 1, open-label trial of ABO2109 in solid tumor (2 arms), sponsored by Abogen Bioscience. Primary endpoints: Dose-Limiting Toxicity at 21 days, Treatment-Emergent Adverse Events at 90 days and 2 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
ABO2109
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07583953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07583953.